Telaglenastat

N/A

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameTelaglenastat
Drug Alias NameCB-839
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutaminase kidney isoform, mitochondrial inhibitors
TargetsGlutaminase kidney isoform, mitochondrial
Therapy Area/IndicationsBrain metastasesSolid tumoursMyelodysplastic Syndromes +[27
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandItaly +[8
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCalithera Biosciences Inc
China Registration ClassN/A

Develop Information

Active IndicationsBrain metastasesSolid tumoursMyelodysplastic Syndromes +[12
Inactive IndicationsProstatic NeoplasmsOvarian NeoplasmsColorectal Neoplasms +[15

Other Information

ATC CodeN/A
Related LinksN/A